Odd Terje Brustugun
Overview
Explore the profile of Odd Terje Brustugun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
3475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nyen J, Booth A, Husby O, Bugge C, Engebretsen I, Oteiza F, et al.
Front Oncol
. 2025 Mar;
15:1506041.
PMID: 40052133
Objectives: We aimed to describe treatment patterns, time on treatment (ToT) and overall survival (OS) for patients with advanced non-squamous, EGFR+, ALK+ and ROS1+ NSCLC in Norway. Materials And Methods:...
2.
Hektoen H, Tsuruda K, Fjellbirkeland L, Nilssen Y, Brustugun O, Andreassen B
Br J Cancer
. 2024 Nov;
132(1):93-102.
PMID: 39489879
Background: Based on favourable results from clinical trials, immune checkpoint inhibitors (ICI) have become the standard first line (1 L) systemic anticancer treatment (SACT) for advanced stage non-small cell lung...
3.
Nymoen H, Alver T, Horndalsveen H, Eide H, Bjaanaes M, Brustugun O, et al.
Front Oncol
. 2024 Aug;
14:1412716.
PMID: 39148905
Background: Radiotherapy (RT) can be used to reduce symptoms and maintain open airways for patients with non-small cell lung cancer when systemic treatment is not sufficient. For some patients, tumor...
4.
Laerum D, Strand T, Brustugun O, Gallefoss F, Falk R, Durheim M, et al.
Acta Oncol
. 2024 May;
63:343-350.
PMID: 38751329
Background: Whether sex is an independent prognostic factor in lung cancer survival is the subject of ongoing debate. Both large national registries and single hospital studies have shown conflicting findings....
5.
Nilssen Y, Brustugun O, Fjellbirkeland L, Gronberg B, Haram P, Helbekkmo N, et al.
Clin Lung Cancer
. 2024 May;
25(5):e221-e228.e3.
PMID: 38692990
Introduction/background: There has been a marked survival improvement for patients with non-small-cell lung cancer. We describe the national trends in characteristics and survival, and geographical differences in diagnostic workup, treatment,...
6.
Nilssen Y, Brustugun O, Fjellbirkeland L, Helland A, Moller B, Wahl S, et al.
BMC Pulm Med
. 2024 Mar;
24(1):106.
PMID: 38439038
Background: The main focus on the characteristics of malignant lung tumours has been the size, position within the lobe, and infiltration into neighbouring structures. The aim of this study was...
7.
Dyrbekk A, Warsame A, Suhrke P, Ludahl M, Zecic N, Moe J, et al.
Clin Exp Med
. 2024 Jan;
24(1):10.
PMID: 38240952
Tropomyosin receptor kinases (TRK) are attractive targets for cancer therapy. As TRK-inhibitors are approved for all solid cancers with detectable fusions involving the Neurotrophic tyrosine receptor kinase (NTRK)-genes, there has...
8.
Nilssen Y, Solberg S, Brustugun O, Moller B, Sundset A, Wahl S, et al.
Eur J Cardiothorac Surg
. 2023 Jun;
64(1).
PMID: 37348858
Objectives: The incidence of tracheal cancer is low, few clinicians get much experience and the awareness may be low. Recent data on the treatment and outcome are limited. The aim...
9.
Dyrbekk A, Warsame A, Suhrke P, Ludahl M, Moe J, Eide I, et al.
Diagn Pathol
. 2023 May;
18(1):70.
PMID: 37237384
Background: ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions...
10.